RESUMEN
Using DNA comet assay we found that polysaccharides from Tussilago farfara L. reduced the intensity of polychemotherapy-induced apoptosis and DNA damage in bone marrow cells and small intestinal epithelium of C57Bl/6 mice, which attested to genoprotective properties of these polysaccharides.
Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/antagonistas & inhibidores , Células de la Médula Ósea/efectos de los fármacos , ADN/química , Mucosa Intestinal/efectos de los fármacos , Polisacáridos/farmacología , Tussilago/química , Animales , Antineoplásicos Fitogénicos/aislamiento & purificación , Protocolos de Quimioterapia Combinada Antineoplásica/toxicidad , Apoptosis/efectos de los fármacos , Células de la Médula Ósea/citología , Células de la Médula Ósea/metabolismo , Cisplatino/antagonistas & inhibidores , Cisplatino/toxicidad , Ensayo Cometa , ADN/metabolismo , Duodeno/citología , Duodeno/efectos de los fármacos , Duodeno/metabolismo , Femenino , Inyecciones Intraperitoneales , Mucosa Intestinal/citología , Mucosa Intestinal/metabolismo , Irinotecán/antagonistas & inhibidores , Irinotecán/toxicidad , Ratones , Ratones Endogámicos C57BL , Paclitaxel/antagonistas & inhibidores , Paclitaxel/toxicidad , Extractos Vegetales/química , Polisacáridos/aislamiento & purificaciónRESUMEN
MATERIAL AND METHODS: The authors carried out a p53 genetic research on native DNA in 15 oral-maxillofacial squamous cell carcinomas, lymph nodes metastasis, treated with neoadjuvant chemotherapy, checking the p53 "status" and the clinical response to the chemotherapeutic treatment (three 5-FU/CDDP cycles). RESULTS: The authors found p53 mutations in 3/15 cases. In these cases, at post-chemo restaging, it resulted 2 progressions and 1 stability of disease. In the 12 cases with wildtype p53: 4 objective improvements and partial responses (PR), respectively, of 55% (1), 60% (1), 65% (1), 70% (1), 75% (2) and 90% (2). The 15 patients were treated then by surgery and adjuvant chemotherapy (three C-F cycles). These results seem to confirm the outcome of the researches "in vitro" and they provide first correlations between p53 mutations and chemoresistance in oral squamous cell carcinomas. The survival evaluation also, in the examined cases, shows, but with medium-term follow-up, the tendency to a poor prognosis when p53 is altered. CONCLUSIONS: This research outlines the possibility, also for oral and maxillofacial tumors, to utilize, p53 as a prognostic and chemoresponse marker, useful, with the otherwise well-known prognostic factors, for the evaluation of advanced cancers, in the interests of a more suitable therapeutic protocol.